[Skip to Content]
[Skip to Content Landing]

Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer

A 2019 study reported that high tumor-stroma proportion (≥50% stroma) at initial ovarian carcinoma diagnosis was associated with emergence of platinum chemoresistance. JAMA Oncology Editor Mary (Nora) Disis, MD, of the University of Washington in Seattle explains the significance of the findings to JAMA Medical News senior staff writer Jennifer Abbasi.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Name Your Search

Save Search

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Topics
State Requirements